2d:I[856015,["/_next/static/immutable/chunks/1xzisbplk9czp.js","/_next/static/immutable/chunks/3j2i1faptc_-9.js","/_next/static/immutable/chunks/0fma7nlq6immz.js","/_next/static/immutable/chunks/08tq8rmv423j5.js","/_next/static/immutable/chunks/1chr5wkk3j58k.js","/_next/static/immutable/chunks/37kmmh_zm4dov.js","/_next/static/immutable/chunks/311zvdjfxff-f.js","/_next/static/immutable/chunks/1a_hqhrsle_n_.js"],"default"] 2e:T64b2,

Summary Table

Domain	Details
Risk Factors	Rh-negative mother with prior Rh-positive pregnancy (or prior miscarriage, abortion, ectopic, amniocentesis, or trauma without prophylaxis); ABO incompatibility (mother type O, infant type A or B); prior sensitizing blood transfusion
Etiology	Maternal IgG alloantibodies cross the placenta and bind fetal red blood cells, triggering extravascular hemolysis in the fetal reticuloendothelial system
Patient Presentation	Ranges from mild neonatal jaundice within the first 24 hours of life to severe fetal anemia with hydrops fetalis (generalized edema, ascites, pleural/pericardial effusions)
Classic Physical Exam	Jaundice appearing within the first 24 hours, pallor, hepatosplenomegaly, generalized edema (hydrops); in severe cases, signs of heart failure
Key Diagnostic Results	Positive direct Coombs test (direct antiglobulin test) on neonatal blood; elevated indirect bilirubin; reticulocytosis; positive indirect Coombs test on maternal serum; elevated middle cerebral artery peak systolic velocity on Doppler
Management	Phototherapy for mild to moderate hyperbilirubinemia; exchange transfusion for severe or rapidly rising bilirubin; intrauterine transfusion for severe fetal anemia; anti-D immunoglobulin (RhoGAM) at 28 weeks and within 72 hours postpartum for prevention
Keywords	"Jaundice within first 24 hours," "Rh-negative mother," "positive direct Coombs test," "hydrops fetalis," "erythroblastosis fetalis," "kernicterus"

1. Pathophysiology

Hemolytic disease of the newborn occurs when a maternal-fetal blood group incompatibility leads to maternal antibody production against fetal red blood cell antigens. The two principal forms are Rh (anti-D) incompatibility and ABO incompatibility, though minor antigens (anti-Kell, anti-Duffy, anti-Kidd) can also cause disease.

In Rh disease, the critical event is maternal sensitization. During the first pregnancy with an Rh-positive fetus, small volumes of fetal blood enter the maternal circulation at delivery (fetomaternal hemorrhage). The Rh-negative mother mounts an initial IgM response, which cannot cross the placenta and therefore does not harm the first child. However, in any subsequent Rh-positive pregnancy, re-exposure triggers a rapid anamnestic IgG response. These IgG antibodies freely cross the placenta, coat fetal red blood cells, and mark them for destruction by splenic and hepatic macrophages through extravascular hemolysis. This is why the classic teaching is that the first Rh-incompatible pregnancy is usually unaffected, while the second and subsequent pregnancies carry increasing risk.

The accelerated hemolysis produces several downstream consequences. The fetal liver ramps up extramedullary hematopoiesis to compensate for red cell loss, which explains the hepatosplenomegaly. Massive red cell destruction releases hemoglobin that is metabolized to unconjugated (indirect) bilirubin. Because the fetus clears bilirubin through the placenta, severe jaundice typically manifests only after birth, when the neonatal liver (with its immature UDP-glucuronosyltransferase activity) cannot conjugate bilirubin fast enough. When unconjugated bilirubin exceeds the albumin-binding capacity, free bilirubin crosses the blood-brain barrier and deposits in the basal ganglia, hippocampus, and brainstem nuclei, causing kernicterus (chronic bilirubin encephalopathy). Clinically, early bilirubin encephalopathy presents with lethargy, hypotonia, and poor feeding, progressing to opisthotonus, high-pitched cry, and seizures.

In the most severe form, profound fetal anemia leads to high-output cardiac failure, with resultant generalized edema, ascites, pleural and pericardial effusions, and placental edema, collectively termed hydrops fetalis. This represents the end-stage of the disease and carries a high mortality rate.

In ABO incompatibility, the mechanism differs slightly. A type O mother naturally carries anti-A and anti-B IgG antibodies even without prior sensitization, which means the first pregnancy can be affected. However, ABO disease is generally milder because A and B antigens are expressed on many tissue types (not just red cells), which dilutes the antibody effect. The hemolysis is less severe, hydrops is rare, and the clinical picture is typically limited to neonatal jaundice.

Anti-Kell antibodies deserve mention because they suppress erythropoiesis at the progenitor level rather than causing hemolysis of mature red cells. This means that anti-Kell disease can cause severe fetal anemia with a disproportionately low reticulocyte count and less hyperbilirubinemia than expected for the degree of anemia.

2. Classification and Clinical Manifestation

Severity	Findings	Mechanism	Prognosis
Mild (approximately 50% of Rh disease)	Mild anemia, jaundice appearing after 24 hours, minimal hepatosplenomegaly	Low-level antibody-mediated hemolysis, adequate compensatory erythropoiesis	Excellent with phototherapy alone
Moderate (approximately 25%)	Significant jaundice within first 24 hours, moderate anemia (hemoglobin 9 to 12 g/dL), hepatosplenomegaly, reticulocytosis, circulating nucleated red blood cells (erythroblasts)	Higher antibody titer driving increased hemolysis, extramedullary hematopoiesis beginning to expand	Requires close monitoring; may need exchange transfusion
Severe / Hydrops Fetalis (approximately 25%)	Generalized edema, ascites, pleural and pericardial effusions, severe pallor, massive hepatosplenomegaly, placentomegaly	Profound anemia (hemoglobin below 7 g/dL), high-output cardiac failure, hypoalbuminemia from hepatic dysfunction and capillary leak	High mortality without intrauterine transfusion; risk of stillbirth

3. Diagnostic Workup

Test	Role	Key Findings
Maternal blood type and antibody screen (indirect Coombs test)	Best initial screening test at first prenatal visit	Identifies Rh-negative status; detects circulating anti-D or other alloantibodies
Antibody titer	Quantifies maternal antibody level	Critical titer of 1:16 or greater (anti-D) warrants further fetal surveillance
Paternal blood typing and zygosity	Determines likelihood of fetal Rh-positivity	If father is homozygous Rh-positive, all offspring will be Rh-positive
Cell-free fetal DNA in maternal blood	Non-invasive determination of fetal Rh status	Confirms whether the fetus is Rh-positive (obviates invasive testing if fetus is Rh-negative)
Middle cerebral artery Doppler (peak systolic velocity)	Best non-invasive test for fetal anemia	Peak systolic velocity greater than 1.5 multiples of the median indicates moderate to severe anemia
Amniocentesis with spectrophotometry (delta OD450)	Previously standard for assessing severity	Elevated optical density at 450 nm correlates with bilirubin level in amniotic fluid; largely replaced by MCA Doppler
Cordocentesis (percutaneous umbilical blood sampling)	Most accurate test for fetal anemia	Direct measurement of fetal hemoglobin, hematocrit, blood type, and direct Coombs test; also allows immediate intrauterine transfusion
Direct Coombs test on neonatal cord blood	Confirms diagnosis postnatally	Positive result indicates antibody-coated fetal red blood cells
Neonatal bilirubin (total and direct fractions)	Guides postnatal treatment	Elevated indirect bilirubin; rate of rise guides phototherapy versus exchange transfusion decisions

The diagnostic approach begins during prenatal care. Every pregnant woman should have blood type and Rh status determined at the first prenatal visit, along with an indirect Coombs test (antibody screen). If the mother is Rh-negative and the screen is negative, prophylaxis with anti-D immunoglobulin is given at 28 weeks and repeated postpartum. If the indirect Coombs test is positive, the next step is to determine the antibody identity and titer. For anti-D antibodies, a titer of 1:16 or greater is considered the critical threshold that warrants further fetal surveillance.

Once the critical titer is reached, the key question becomes "how anemic is the fetus?" The best non-invasive method to answer this is middle cerebral artery (MCA) Doppler ultrasonography. An anemic fetus compensates by increasing cardiac output and reducing blood viscosity, which raises the peak systolic velocity in the MCA. A value exceeding 1.5 multiples of the median (MoM) for gestational age correlates with moderate to severe anemia and is the indication for cordocentesis or delivery depending on gestational age. This has largely replaced serial amniocentesis with delta OD450 (Liley curve), which was the previous standard.

Cordocentesis remains the most accurate test because it allows direct sampling of fetal blood for hemoglobin, hematocrit, blood type, reticulocyte count, and direct Coombs test. It also serves a therapeutic function because intrauterine transfusion can be performed through the same needle.

Postnatally, the direct Coombs test on cord blood is the confirmatory test. A positive result, combined with evidence of hemolysis (elevated indirect bilirubin, reticulocytosis, anemia), clinches the diagnosis. In ABO incompatibility, the direct Coombs may be only weakly positive or even negative because the A and B antigens are less densely expressed on neonatal red cells. In this setting, spherocytes on the peripheral smear become a helpful clue.

A critical point: any jaundice presenting within the first 24 hours of life is pathologic until proven otherwise, and hemolytic disease must be at the top of the differential.

4. Management and Treatment

Clinical Scenario	Intervention	Details
Prevention (unsensitized Rh-negative mother)	Anti-D immunoglobulin (RhoGAM)	300 mcg intramuscularly at 28 weeks gestation AND within 72 hours postpartum if infant is Rh-positive; also after any sensitizing event (miscarriage, amniocentesis, abdominal trauma, ectopic)
Fetal anemia (before viability or remote from term)	Intrauterine transfusion	Type O, Rh-negative, leukoreduced, irradiated packed red blood cells delivered via cordocentesis into the umbilical vein; may need to be repeated every 2 to 4 weeks
Mild to moderate neonatal hyperbilirubinemia	Phototherapy	Blue-green light (wavelength 460 to 490 nm) converts unconjugated bilirubin into water-soluble photoisomers excreted without conjugation; threshold depends on gestational age, postnatal age, and risk factors per the Bhutani nomogram
Severe or rapidly rising bilirubin / signs of acute bilirubin encephalopathy	Exchange transfusion	Double-volume exchange (approximately 160 to 170 mL/kg) removes antibody-coated red cells and circulating bilirubin while correcting anemia; performed when bilirubin exceeds the exchange threshold or rises more than 0.5 mg/dL per hour despite intensive phototherapy
Adjunctive postnatal therapy	Intravenous immunoglobulin (IVIG)	0.5 to 1 g/kg over 2 hours; reduces the need for exchange transfusion by blocking Fc receptors on reticuloendothelial macrophages; considered when bilirubin continues rising despite intensive phototherapy
Late anemia (weeks after birth)	Erythropoietin and iron supplementation, or simple packed red cell transfusion	Ongoing low-grade hemolysis and suppressed erythropoiesis (especially after intrauterine transfusions) can cause anemia at 4 to 6 weeks; monitor hemoglobin and reticulocyte count

Prevention is the highest-yield concept for this topic. Anti-D immunoglobulin works by binding and clearing fetal Rh-positive red cells from the maternal circulation before the maternal immune system can mount an antibody response. The standard dose of 300 mcg covers approximately 30 mL of fetal whole blood (15 mL of packed red cells). If a larger fetomaternal hemorrhage is suspected (as in placental abruption), a Kleihauer-Betke test or flow cytometry quantifies the volume of fetal blood in the maternal circulation so that additional doses can be administered.

For the already sensitized mother, prevention is no longer possible and management shifts to monitoring and intervention. Serial MCA Doppler studies are performed every 1 to 2 weeks beginning around 18 to 20 weeks. When the MCA peak systolic velocity exceeds 1.5 MoM, intrauterine transfusion is the next step if the fetus is too premature for delivery (generally before 32 to 34 weeks). The blood used must be type O, Rh-negative, CMV-negative, irradiated, and leukoreduced to prevent graft-versus-host disease and alloimmunization. If the fetus is near term (34 weeks or beyond), delivery with postnatal management is preferred.

Postnatally, the cornerstone is phototherapy, which should be initiated based on hour-of-life bilirubin plotted on the appropriate risk-stratified nomogram. Phototherapy works by photoisomerization, converting the toxic 4Z,15Z-bilirubin isomer into water-soluble geometric and structural isomers (primarily lumirubin) that can be excreted in bile and urine without hepatic conjugation.

Exchange transfusion is reserved for neonates whose bilirubin reaches the exchange threshold, rises at a rate exceeding 0.5 mg/dL per hour despite intensive phototherapy, or who show clinical signs of acute bilirubin encephalopathy (hypertonia, retrocollis, opisthotonus, fever, high-pitched cry). The double-volume exchange replaces approximately 85% of the neonate's circulating red blood cells, simultaneously removing bilirubin and maternal antibodies. Complications include electrolyte disturbances (hypocalcemia from citrate in banked blood), thrombocytopenia, infection, and necrotizing enterocolitis, which is why it is used as a second-line measure.

IVIG is an adjunctive therapy that can reduce the rate of exchange transfusion. It competitively blocks Fc receptors on macrophages, decreasing the rate of antibody-mediated red cell destruction.

An important contraindication to note: in neonates with hemolytic disease, do not delay phototherapy while waiting for confirmatory tests. Early, aggressive phototherapy reduces the likelihood of needing exchange transfusion.

5. Differential Diagnosis and Distractors

Differential Diagnosis	Why It Looks Similar	Key Discriminator
Physiologic jaundice of the newborn	Also presents with neonatal jaundice	Onset after 24 hours (typically day 2 to 3), indirect bilirubin below 12 to 13 mg/dL in term infants, self-limited, direct Coombs test negative
Breast milk jaundice	Prolonged indirect hyperbilirubinemia in a breastfed infant	Onset after day 5 to 7, peaks at week 2, benign course; direct Coombs test negative; no anemia or reticulocytosis
Breastfeeding jaundice (starvation jaundice)	Early jaundice in breastfed newborn	Due to insufficient caloric intake and decreased stooling (reduced bilirubin elimination); presents in first week; no hemolysis; improves with increased feeding
G6PD deficiency	Hemolytic jaundice in a newborn, positive for indirect hyperbilirubinemia	Triggered by oxidative stressors; Heinz bodies and bite cells on peripheral smear (not spherocytes); direct Coombs test negative; often in males of Mediterranean, African, or Asian descent
Hereditary spherocytosis	Spherocytes on smear, jaundice, anemia, splenomegaly	Family history of anemia or splenectomy; direct Coombs test negative; diagnosed by eosin-5-maleimide (EMA) binding test or osmotic fragility; autosomal dominant
Neonatal sepsis	Can present with jaundice, pallor, poor feeding in a newborn	Typically associated with temperature instability, lethargy, respiratory distress; elevated CRP, positive blood culture; no reticulocytosis unless DIC develops
Biliary atresia	Jaundice in a newborn	Presents with direct (conjugated) hyperbilirubinemia, pale acholic stools, dark urine; onset typically at 2 to 4 weeks; this is an obstructive process, not hemolytic
TORCH infections	Can cause neonatal anemia, jaundice, hepatosplenomegaly	Additional findings such as microcephaly, intracranial calcifications, chorioretinitis, rash, thrombocytopenia; direct Coombs test negative

The main exam trap is confusing ABO incompatibility with hereditary spherocytosis, because both show spherocytes on the peripheral smear and indirect hyperbilirubinemia. The direct Coombs test is the discriminator: positive (or weakly positive) in ABO disease, negative in hereditary spherocytosis. Family history and chronicity also help, as hereditary spherocytosis typically presents with recurrent hemolytic episodes beyond the neonatal period.

6. Traps and High-Yield Pearls

The single most common trap on this topic is confusing the indirect Coombs test with the direct Coombs test. The indirect Coombs test detects free antibodies in the mother's serum (a screening and prenatal surveillance tool), while the direct Coombs test detects antibodies already bound to the neonatal red cell surface (the postnatal confirmatory test). A vignette describing a jaundiced neonate with known maternal Rh-negative status is asking for the direct Coombs test on the baby's blood, not the indirect Coombs on the mother.

Another frequently tested concept is the timing of jaundice. Any jaundice appearing within the first 24 hours is pathologic and should trigger an immediate workup for hemolysis. Vignettes describing jaundice at "12 hours of life" or "shortly after birth" are pointing toward hemolytic disease, not physiologic jaundice.

Students also commonly forget that ABO incompatibility can affect the first pregnancy (because preformed IgG anti-A and anti-B antibodies exist naturally in type O mothers), while Rh disease classically spares the first pregnancy. A vignette with a primiparous type O mother and a jaundiced type A or B newborn is classic for ABO disease.

The MCA Doppler question is increasingly tested: when a vignette presents an Rh-sensitized mother with rising titers beyond the critical threshold, the next best step is MCA Doppler, not amniocentesis and not immediate delivery. Cordocentesis is reserved for when MCA Doppler confirms severe anemia (greater than 1.5 MoM) and the fetus is too premature for delivery.

Finally, always remember that RhoGAM is useless once sensitization has occurred. If the indirect Coombs test is already positive, anti-D immunoglobulin will not reverse it. RhoGAM prevents sensitization; it does not treat it. This is a classic distractor in management questions where students select "administer RhoGAM" for an already sensitized mother.

The core competency being tested across all question styles on this topic is the ability to sequence the diagnostic and management algorithm correctly: prenatal screening with indirect Coombs, monitoring with titers and MCA Doppler, intervention with intrauterine transfusion or delivery, and postnatal management with phototherapy and exchange transfusion, all layered on the foundation of prevention with anti-D immunoglobulin.

1e:["$","$L2d",null,{"article":{"id":"ff593646-d0b7-47ce-9cf0-046d66fe5bb9","title":"Hemolytic Disease of the Newborn (HDFN)","content":"$2e","category":"Reproduksi","created_at":"2026-05-16T11:50:13.197537+00:00","status":"published","subcategory":null},"questionCount":1,"sections":[{"id":"section-pathophysiology","num":"01","title":"Pathophysiology"},{"id":"section-classification-and-clinical-manifestation","num":"02","title":"Classification and Clinical Manifestation"},{"id":"section-diagnostic-workup","num":"03","title":"Diagnostic Workup"},{"id":"section-management-and-treatment","num":"04","title":"Management and Treatment"},{"id":"section-differential-diagnosis-and-distractors","num":"05","title":"Differential Diagnosis and Distractors"},{"id":"section-traps-and-high-yield-pearls","num":"06","title":"Traps and High-Yield Pearls"}],"hasSummaryTable":true}]